ID   DM13
AC   CVCL_6621
SY   DM-13; Duke Melanoma 13
DR   cancercelllines; CVCL_6621
DR   GEO; GSM1572817
DR   GEO; GSM1572818
DR   GEO; GSM1572819
DR   GEO; GSM1572820
DR   GEO; GSM1572821
DR   GEO; GSM1572822
DR   GEO; GSM1671960
DR   GEO; GSM1671989
DR   GEO; GSM1672012
DR   GEO; GSM1672071
DR   GEO; GSM1672076
DR   GEO; GSM1672098
DR   GEO; GSM1672101
DR   GEO; GSM1672115
DR   GEO; GSM1672131
DR   Wikidata; Q54831199
RX   PubMed=2404572;
RX   PubMed=2785141;
RX   PubMed=7703289;
RX   PubMed=10752474;
RX   PubMed=14871852;
RX   PubMed=21654344;
RX   PubMed=26405815;
RX   PubMed=26673621;
CC   From: Duke University Medical Center; Durham; USA.
CC   HLA typing: A*02,31; B*13,18 (PubMed=2404572).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 19
//
RX   PubMed=2404572;
RA   Crowley N.J., Slingluff C.L. Jr., Darrow T.L., Seigler H.F.;
RT   "Generation of human autologous melanoma-specific cytotoxic T-cells
RT   using HLA-A2-matched allogeneic melanomas.";
RL   Cancer Res. 50:492-498(1990).
//
RX   PubMed=2785141; DOI=10.4049/jimmunol.142.9.3329;
RA   Darrow T.L., Slingluff C.L. Jr., Seigler H.F.;
RT   "The role of HLA class I antigens in recognition of melanoma cells by
RT   tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor
RT   antigens.";
RL   J. Immunol. 142:3329-3335(1989).
//
RX   PubMed=7703289; DOI=10.1089/hum.1995.6.1-87;
RA   Fenton R.T., Sznol M., Luster D.G., Taub D.D., Longo D.L.;
RT   "A phase I trial of B7-transfected or parental lethally irradiated
RT   allogeneic melanoma cell lines to induce cell-mediated immunity
RT   against tumor-associated antigen presented by HLA-A2 or HLA-A1 in
RT   patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol
RT   9401.";
RL   Hum. Gene Ther. 6:87-106(1995).
//
RX   PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. 3rd, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//